BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 10948447)

  • 21. SERMs: meeting the promise of multifunctional medicines.
    Jordan VC
    J Natl Cancer Inst; 2007 Mar; 99(5):350-6. PubMed ID: 17341726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.
    Riggs BL; Hartmann LC
    N Engl J Med; 2003 Feb; 348(7):618-29. PubMed ID: 12584371
    [No Abstract]   [Full Text] [Related]  

  • 23. Third-generation SERMs may face uphill battle.
    Schmidt C
    J Natl Cancer Inst; 2010 Nov; 102(22):1690-2. PubMed ID: 21060064
    [No Abstract]   [Full Text] [Related]  

  • 24. Altering the propensity for density: the benefits and risks of selective estrogen receptor modulators.
    Vogel VG
    Menopause; 2009; 16(6):1079-82. PubMed ID: 19779314
    [No Abstract]   [Full Text] [Related]  

  • 25. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Raloxifene: a selective modulator of estrogen receptors].
    van den Brûle FA; Kalbus MF; Gaspard UJ
    J Gynecol Obstet Biol Reprod (Paris); 1999 Dec; 28(8):788-99. PubMed ID: 10635481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experts hopeful about designer estrogens. For some women, selective estrogen receptor modulators (SERMs) help prevent breast cancer.
    Runowicz CD
    Health News; 2003 Apr; 9(4):1-2. PubMed ID: 12710388
    [No Abstract]   [Full Text] [Related]  

  • 28. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
    Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex steroids and breast cancer prevention.
    Spicer DV; Pike MC
    J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The science of selective estrogen receptor modulators: concept to clinical practice.
    Jordan VC
    Clin Cancer Res; 2006 Sep; 12(17):5010-3. PubMed ID: 16951214
    [No Abstract]   [Full Text] [Related]  

  • 33. Breast cancer chemoprevention.
    Mamounas EP
    Hematol Oncol Clin North Am; 2000 Jun; 14(3):727-38. PubMed ID: 11203331
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamoxifen and raloxifene may benefit women at high risk for breast cancer.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Jul; 13(14):1-2, 5. PubMed ID: 12518771
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical experience with raloxifene].
    Szúcs J; Pávó I; Jurida N
    Orv Hetil; 2000 Jan; 141(5):237-40. PubMed ID: 10697982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raloxifene for the treatment and prevention of breast cancer?
    Pappas SG; Jordan VC
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):334-40. PubMed ID: 12113100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.
    Jordan VC
    Ann N Y Acad Sci; 2001 Dec; 952():60-72. PubMed ID: 11795444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Raloxifene hydrochloride].
    Itabashi A
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
    [No Abstract]   [Full Text] [Related]  

  • 40. Selective estrogen-receptor modulators in 2001.
    O'Regan RM; Gradishar WJ
    Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.